A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Nemtabrutinib; Drug: Efavirenz

Study type: Interventional

Funder types: Industry

Identifiers

NCT06698016

1026-014

Details and patient eligibility

About

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called efavirenz.

Enrollment: 16 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria

The key inclusion criteria include but are not limited to the following:

• Is in good health based on medical history, physical examination, vital sign (VS) measurements, electrocardiograms (ECGs) and laboratory safety tests performed before allocation
• Has a body mass index (BMI) > 18 kg/m2 and ≤ 32 kg/m^2

Exclusion Criteria

The key exclusion criteria include but are not limited to the following:

• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
• Has a history of cancer (malignancy)

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

16 participants in 2 patient groups

Period 1: Nemtabrutinib

Experimental group

Description:

Participants receive a single dose of nemtabrutinib followed by a protocol specified wash-out period.

Treatment:

Drug: Nemtabrutinib

Period 2: Nemtabrutinib + Efavirenz

Experimental group

Description:

Participants receive oral doses of efavirenz once daily on Days 1 to 24 with a single oral dose of nemtabrutinib given with efavirenz on Day 11.

Treatment:

Drug: Efavirenz

Drug: Nemtabrutinib